RU2004134331A - Антиген muc1 со сниженным числом повторяющихся vntr-блоков - Google Patents
Антиген muc1 со сниженным числом повторяющихся vntr-блоков Download PDFInfo
- Publication number
- RU2004134331A RU2004134331A RU2004134331/13A RU2004134331A RU2004134331A RU 2004134331 A RU2004134331 A RU 2004134331A RU 2004134331/13 A RU2004134331/13 A RU 2004134331/13A RU 2004134331 A RU2004134331 A RU 2004134331A RU 2004134331 A RU2004134331 A RU 2004134331A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- vntr
- protein
- muc1
- Prior art date
Links
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title claims 6
- 102100034256 Mucin-1 Human genes 0.000 title claims 6
- 239000000427 antigen Substances 0.000 title claims 3
- 102000036639 antigens Human genes 0.000 title claims 3
- 108091007433 antigens Proteins 0.000 title claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (16)
1. Молекула нуклеиновой кислоты, кодирующая антиген MUC1, причем указанная молекула способна вызывать иммунный ответ in vivo и имеет сниженную подверженность рекомбинации при сравнении с полноразмерным MUC1.
2. Молекула нуклеиновой кислоты, кодирующая антиген MUC1, содержащий от 1 до 15 полностью повторяющихся VNTR-блоков.
3. Молекула нуклеиновой кислоты по п.2, содержащая менее чем 8 полностью повторяющихся VNTR-блоков.
4. Молекула нуклеиновой кислоты по п.1 или 2, где по меньшей мере один VNTR мутирован для снижения потенциала гликозилирования.
5. Молекула нуклеиновой кислоты по п.1 или 2, которая включает в себя последовательности, кодирующие эпитоп, выбранный из группы: FLSFHISNL, NSSLEDPSTDYYQELQRDISE и NLTISDVSV.
6. Молекула нуклеиновой кислоты по пп.1 или 2, где эта молекула представляет собой молекулу ДНК.
7. Плазмида, содержащая молекулу ДНК по п.6.
8. Протеин, кодируемый нуклеиновой кислотой по любому из пп.1-6.
9. Фармацевтическая композиция, содержащая нуклеиновую кислоту по пп.1-6, или плазмиду по п.7, или протеин по п.8 и фармацевтический приемлемый эксципиент, разбавитель или носитель.
10. Фармацевтическая композиция по п.9, где носитель представляет собой микрочастицу.
11. Фармацевтическая композиция по п.10, где микрочастица является золотой.
12. Фармацевтическая композиция по п.9, содержащая адъювант.
13. Нуклеиновая кислота по п.1 или 2, плазмида по п.7, протеин по п.8 или фармацевтическая композиция по пп.9-12 для применения в медицине.
14. Применение нуклеиновой кислоты по любому из пп.1-6 в изготовлении медикамента для лечения или предотвращения опухолей, экспрессирующих MUC1.
15. Применение протеина по п.8 в изготовлении медикамента для лечения или предотвращения опухолей, экспрессирующих MUC1.
16. Способ лечения или предотвращения опухолей или метастазов, при котором вводят безопасное и эффективное количество нуклеиновой кислоты по пп.1-6, плазмиды по п.7 или протеина по п.8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212046.7A GB0212046D0 (en) | 2002-05-24 | 2002-05-24 | Vaccines |
| GB0212046.7 | 2002-05-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004134331A true RU2004134331A (ru) | 2005-08-27 |
| RU2303069C2 RU2303069C2 (ru) | 2007-07-20 |
Family
ID=9937394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004134331/13A RU2303069C2 (ru) | 2002-05-24 | 2003-05-23 | Антиген muc1 со сниженным числом повторяющихся vntr-блоков |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060251665A1 (ru) |
| EP (1) | EP1527177A2 (ru) |
| JP (1) | JP2005526520A (ru) |
| KR (1) | KR20050004211A (ru) |
| CN (1) | CN100408682C (ru) |
| AR (1) | AR039846A1 (ru) |
| AU (1) | AU2003240729B2 (ru) |
| BR (1) | BR0311211A (ru) |
| CA (1) | CA2485816A1 (ru) |
| GB (1) | GB0212046D0 (ru) |
| IL (1) | IL165156A0 (ru) |
| IS (1) | IS7526A (ru) |
| MX (1) | MXPA04011527A (ru) |
| NO (1) | NO20044947L (ru) |
| NZ (1) | NZ536668A (ru) |
| PL (1) | PL374569A1 (ru) |
| RU (1) | RU2303069C2 (ru) |
| TW (1) | TW200407426A (ru) |
| WO (1) | WO2003100060A2 (ru) |
| ZA (1) | ZA200409445B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| US8901093B2 (en) | 2003-11-12 | 2014-12-02 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Custom vectors for treating and preventing pancreatic cancer |
| WO2005046614A2 (en) * | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | System for treating and preventing breast cancer |
| ATE527285T1 (de) * | 2005-01-28 | 2011-10-15 | Univ Ramot | Anti-muc1-alpha-beta-antikörper |
| US20120039984A1 (en) | 2008-07-03 | 2012-02-16 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| CN106215179A (zh) * | 2010-06-11 | 2016-12-14 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| CN103209701B (zh) * | 2010-06-11 | 2016-08-03 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| CN105193724A (zh) * | 2011-02-24 | 2015-12-30 | 肿瘤防护公司 | 含有佐剂的以muc1 为基础的糖脂肽疫苗 |
| ES2811523T3 (es) * | 2016-01-19 | 2021-03-12 | Pfizer | Vacunas contra el cáncer |
| EP3518964A2 (en) | 2016-09-28 | 2019-08-07 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| HRP20240756T1 (hr) | 2018-05-18 | 2024-09-13 | Daiichi Sankyo Co., Ltd. | Anti-muc1-eksatekan antitijelo-lijek konjugat |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2264145T3 (es) * | 1995-11-30 | 2006-12-16 | The Board Of Regents, The University Of Texas System | Metodos y composiciones para el tratamiento de cancer. |
| EP1012276A2 (en) * | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Ｍｕｃ−１由来のペプチド |
| GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| JP2003533181A (ja) * | 2000-02-01 | 2003-11-11 | ジ・オースティン・リサーチ・インスティテュート | ムチン−１誘導抗原および免疫療法におけるその使用 |
| WO2002062319A2 (en) * | 2001-01-19 | 2002-08-15 | Corixa Corporation | Microsphere delivery of mucin peptides |
| US7125663B2 (en) * | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| US20060069238A1 (en) * | 2002-04-15 | 2006-03-30 | Biomira, Inc. | Synthetic glyco-lipo-peptides as vaccines |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
-
2002
- 2002-05-24 GB GBGB0212046.7A patent/GB0212046D0/en not_active Ceased
-
2003
- 2003-05-22 AR ARP030101782A patent/AR039846A1/es unknown
- 2003-05-22 TW TW092113870A patent/TW200407426A/zh unknown
- 2003-05-23 KR KR10-2004-7018958A patent/KR20050004211A/ko not_active Ceased
- 2003-05-23 US US10/515,871 patent/US20060251665A1/en not_active Abandoned
- 2003-05-23 WO PCT/EP2003/005594 patent/WO2003100060A2/en not_active Ceased
- 2003-05-23 CA CA002485816A patent/CA2485816A1/en not_active Abandoned
- 2003-05-23 JP JP2004508299A patent/JP2005526520A/ja active Pending
- 2003-05-23 EP EP03730134A patent/EP1527177A2/en not_active Withdrawn
- 2003-05-23 BR BR0311211-0A patent/BR0311211A/pt not_active IP Right Cessation
- 2003-05-23 CN CNB038171988A patent/CN100408682C/zh not_active Expired - Fee Related
- 2003-05-23 PL PL03374569A patent/PL374569A1/xx unknown
- 2003-05-23 RU RU2004134331/13A patent/RU2303069C2/ru active
- 2003-05-23 NZ NZ536668A patent/NZ536668A/en unknown
- 2003-05-23 MX MXPA04011527A patent/MXPA04011527A/es not_active Application Discontinuation
- 2003-05-23 AU AU2003240729A patent/AU2003240729B2/en not_active Ceased
-
2004
- 2004-11-10 IL IL16515604A patent/IL165156A0/xx unknown
- 2004-11-11 IS IS7526A patent/IS7526A/is unknown
- 2004-11-12 NO NO20044947A patent/NO20044947L/no not_active Application Discontinuation
- 2004-11-23 ZA ZA200409445A patent/ZA200409445B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04011527A (es) | 2005-09-30 |
| JP2005526520A (ja) | 2005-09-08 |
| WO2003100060A3 (en) | 2004-02-19 |
| GB0212046D0 (en) | 2002-07-03 |
| KR20050004211A (ko) | 2005-01-12 |
| NZ536668A (en) | 2007-01-26 |
| RU2303069C2 (ru) | 2007-07-20 |
| BR0311211A (pt) | 2005-03-01 |
| AR039846A1 (es) | 2005-03-02 |
| AU2003240729B2 (en) | 2007-12-20 |
| AU2003240729A1 (en) | 2003-12-12 |
| US20060251665A1 (en) | 2006-11-09 |
| CA2485816A1 (en) | 2003-12-04 |
| NO20044947D0 (no) | 2004-11-12 |
| TW200407426A (en) | 2004-05-16 |
| CN100408682C (zh) | 2008-08-06 |
| NO20044947L (no) | 2005-12-16 |
| IS7526A (is) | 2004-11-11 |
| CN1668746A (zh) | 2005-09-14 |
| ZA200409445B (en) | 2006-02-22 |
| IL165156A0 (en) | 2005-12-18 |
| WO2003100060A2 (en) | 2003-12-04 |
| EP1527177A2 (en) | 2005-05-04 |
| PL374569A1 (en) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4568907B2 (ja) | 免疫賦活オリゴヌクレオチド及びその使用 | |
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| JP2005511076A5 (ru) | ||
| JP2002542827A5 (ru) | ||
| JP2020531032A5 (ru) | ||
| AU6576800A (en) | Use of a polypeptide for detecting, preventing or treating pathological condition associated with a degenerative, neurological or autoimmune disease | |
| JP2008529558A5 (ru) | ||
| KR900701824A (ko) | 동물 감염의 치료 또는 예방을 위한 조성물 및 그 방법 | |
| JP2006512097A5 (ru) | ||
| JP2016513115A5 (ru) | ||
| JP2003500040A5 (ru) | ||
| JP2003530088A5 (ru) | ||
| DA’Dara et al. | A DNA‐prime/protein‐boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection | |
| JP2005526520A5 (ru) | ||
| JP2004203890A (ja) | マクロファージ炎症蛋白変種 | |
| WO2003085093A3 (en) | Antibodies that specifically bind to gmad | |
| JP2003530872A5 (ru) | ||
| JP2006502228A5 (ru) | ||
| JP2005512518A5 (ru) | ||
| WO2003102136A3 (en) | Antibodies that specifically bind to neurokinin b | |
| CA2432971A1 (en) | Polypeptides | |
| WO2003055912A3 (en) | Secreted proteins | |
| WO2003100060A3 (en) | Muc-1 antigen with reduced number of vntr repeat units | |
| RU2005125608A (ru) | Вакцины на основе муцина muc-1 эпителиальных клеток | |
| US6090378A (en) | Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors |